Titterton Lewis Jr Buys Shares of Anixa Biosciences

Titterton Lewis Jr, an insider at Anixa Biosciences, Inc. (NasdaqCM: ANIX), purchased 2,836 shares of the company on June 16, 2026. The shares were bought at an average price of $2.64 each, bringing the total transaction value to $7,487.04.

Insider Buying and Selling at Anixa Biosciences, Inc.

Titterton Lewis Jr's recent purchase is part of a series of insider transactions at Anixa Biosciences. On June 12, 2026, CEO Dr. Amit Kumar acquired 21,000 shares at $2.50 each. Earlier in the year, on January 28, 2026, Arnold Baskies bought 10,000 shares at a price of $3.04 per share.

Other Institutional Activity in Anixa Biosciences

Several institutional investors have made moves in Anixa Biosciences. Vanguard Capital Management LLC significantly increased its holdings by 1,314,982 shares, ending with a total of 1,314,982 shares valued at approximately $3.39 million. Meanwhile, Laird Norton Wetherby Trust Company, LLC reduced its position by 21,700 shares, holding 566,327 shares worth about $1.46 million. UBS Group AG added 92,564 shares, bringing its total to 551,637 shares valued at $1.42 million.

Anixa Biosciences, Inc. Stock Down 22.7%

Shares of Anixa Biosciences (NasdaqCM: ANIX) traded near $2.61. The company has a market capitalization of roughly $88.8 million. Anixa's forward P/E ratio is not meaningful as the company is not currently profitable, with an EPS of -$0.30. The stock has a 52-week range between $2.32 and $5.46. Its 50-day moving average is $2.79, and the 200-day moving average is $3.31.

Analysts Set New Price Targets

Analysts have expressed optimism about Anixa Biosciences. On March 31, 2026, D. Boral Capital maintained its buy rating with a price target of $10.00. The consensus among analysts is a strong buy, with a mean price target of $10.00.

About Anixa Biosciences

Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines for unmet needs in cancer treatment. Based in San Jose, California, and led by CEO Dr. Amit Kumar, the company is working on innovative technologies like chimeric antigen receptor-T cell therapies and cancer vaccines. Anixa aims to tackle various cancers, including ovarian, breast, lung, colon, and prostate. The company was originally known as ITUS Corporation before rebranding in 2018.

Bottom Line

Insider buying activity, such as the recent purchase by Titterton Lewis Jr, often attracts investor attention, although it is not necessarily indicative of future performance. Anixa Biosciences is a small-cap biotechnology firm with a focus on oncology therapies, and its stock is subject to the volatility typical of the biotech sector. Analyst sentiment remains positive, with a strong buy consensus and price targets suggesting potential upside.